Oppenheimer Lowers CalciMedica (NASDAQ:CALC) Price Target to $10.00

CalciMedica (NASDAQ:CALC) had its target price dropped by investment analysts at Oppenheimer from $20.00 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock.

CALC has been the subject of several other reports. Wall Street Zen upgraded CalciMedica to a “sell” rating in a research note on Saturday, January 17th. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a report on Thursday, January 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CalciMedica currently has an average rating of “Hold” and an average target price of $13.00.

CalciMedica Price Performance

Shares of CalciMedica stock opened at $0.73 on Thursday. The stock’s 50-day simple moving average is $2.86 and its 200-day simple moving average is $3.33. CalciMedica has a 52 week low of $0.46 and a 52 week high of $7.20. The company has a market capitalization of $11.44 million, a price-to-earnings ratio of -0.45 and a beta of 0.60. The company has a quick ratio of 4.04, a current ratio of 3.58 and a debt-to-equity ratio of 1.39.

CalciMedica (NASDAQ:CALC) last released its earnings results on Tuesday, March 3rd. The company reported ($0.69) earnings per share (EPS) for the quarter. As a group, analysts expect that CalciMedica will post -2.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On CalciMedica

A number of hedge funds have recently made changes to their positions in the company. Envestnet Asset Management Inc. boosted its stake in CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares during the last quarter. Atria Investments Inc increased its stake in CalciMedica by 20.0% in the 2nd quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock worth $72,000 after acquiring an additional 7,436 shares during the last quarter. Sound View Wealth Advisors Group LLC bought a new stake in CalciMedica in the 2nd quarter worth approximately $32,000. Cetera Investment Advisers raised its holdings in shares of CalciMedica by 33.1% during the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after acquiring an additional 9,045 shares in the last quarter. Finally, Sheets Smith Investment Management purchased a new stake in shares of CalciMedica during the 3rd quarter worth approximately $157,000.

Key CalciMedica News

Here are the key news stories impacting CalciMedica this week:

• Positive Sentiment: HC Wainwright raised its FY2027 and FY2028 EPS forecasts (FY2027 to $(0.86) from $(1.06); FY2028 to $(0.98) from $(1.20)), reducing projected losses in later years — a constructive signal for long‑term outlook. HC Wainwright estimates
• Neutral Sentiment: HC Wainwright kept a “Neutral” rating while publishing detailed quarterly EPS estimates for 2026 (Q1 $(0.31), Q2 $(0.33), Q3 $(0.37), Q4 $(0.43)) and revised FY2026 to $(1.45) — the near‑term outlook remains loss‑making, so catalyst timing is unclear. HC Wainwright estimates
• Neutral Sentiment: Short‑interest filings reported 0 shares outstanding short and a 0.0 days‑to‑cover figure — described as a “large increase” in the feed but numerically inconsistent (NaN/0). This looks like a data/reporting anomaly rather than a confirmed short squeeze or heavy shorting pressure. No direct link available.
• Negative Sentiment: Oppenheimer cut its price target sharply from $20 to $10 (while keeping an “Outperform” rating), which is a notable downward revision of expected upside and may weigh on sentiment despite the retained bullish rating. Oppenheimer price target cut Additional coverage

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.